In the News
Apr 22, 2011
Jeff Forringer, President of IntrnisiQ, LLC was interviewed for this article.
Manufacturers looking at any market for a therapy, branded or generic, are dealing with a more complex interplay of market demand, reimbursement and regulatory compliance. The oncology market takes that complexity up exponentially, and not just because it’s a highly valued market seeing many new therapies being introduced and in the pipeline.